附屬盈喜石藥集團(01093.HK)彈近8%惟盈警金斯瑞(01548.HK)逆同業續吐4.6%
石藥集團(01093.HK)公布，於深圳創業板上市附屬石藥新諾威(300765.SZ)預計今年上半年淨利潤介乎1.23-1.43億人民幣，按年增長12%-30%，主因是生產經營持續穩定發展及銷售收入穩定增長所致。石藥今早逆市高開逾3%重越10天及50天線後，升幅擴大，最高見13.66元(剛為百天線)，半日收13.56元，回升7.8%，為最強藍籌，半日成交增至4,508萬股，涉資5.95億元。同為藍籌中生(01177.HK)承過去兩天吐勢，今早略低開最多續跌2.5%低見8.31元，接近20天線(8.18元)獲承接，掉頭重越10天線(8.6元)，最高見8.98元，半日收8.91元，倒升4.6%，半日成交增至5,969萬股，涉資5.17億元。
其餘醫藥股今早也普遍跑贏大市造好，其中復星醫藥(02196.HK)重越10天及100天線(24.04元及25.72元)，最高見25元，現造24.8元，反覆回升4%。綠葉製藥(02186.HK)重越20天及10天線(5.78元)，最高見5.84元，現造5.8元，回升3%；石四藥(02005.HK)反覆回升3.2%報7.03元，股價重越250天線(6.96元)；麗珠醫藥(01513.HK)反覆回升3%報19.32元，股價重越10天線(18.96元)。威高股份(1066.HK)反覆回升2.7%報7.49元。
不過，發盈警料中績「見紅」金斯瑞生物科技(01548.HK)承上周五回吐失守10天及20天線勢，今早進一步失守50天線(18.48元)，最多跌7.2%低見17.66元，半日收18.14元，續吐4.6%，成交增至583萬股，涉資逾1.04億元。金斯瑞發盈警指，由於推進藥物開發、生產與商業化而在美國和中國開始臨床試驗所產生研發費用大幅提高及進一步加強自有綜合性細胞治療平台上研發投入顯著增加等因素，預計今年上半年虧損2,940-4,420萬美元，扭轉去年同期賺約1,760萬美元。
內地帶動經濟增長「三頭馬車」數據均顯勝市場預期，恆指扭轉早段曾吐400點或1.4%低見28,071接守穩50天線，跟隨滬深股市(扭轉早段曾吐1.5%-1.6%，半日高收倒升0.8%及1.4%)掉頭倒升61點或0.2%，半日收28,532。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
